Medication info

Floqaduro Extended-Release Tablet 10/500 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Nexpharm Korea Co., Ltd.
Appearance
Pink, biconvex, oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 202204066 · Approved 2022.11.10

This product's status changed to Approval withdrawn on 2023.10.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no previous history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no previous history of antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering agents. Since changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m2. Among patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher and less than 60 mL/min/1.73m2, and who do not have other conditions that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum dose of 1000 mg daily. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, administration of this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases. The risk of volume depletion with dapagliflozin should be considered.

Ingredients

Manufacturer
Nexpharm Korea Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used to improve blood sugar control in adults with type 2 diabetes by combining dapagliflozin and metformin. It especially enhances effects by complementing dietary and exercise therapy. For patients whose blood sugar control is insufficient and who have cardiovascular disease or risk factors, consultation with a specialist regarding the cardiovascular events related to dapagliflozin is necessary. This medication effectively supports blood sugar control in diabetic patients.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no previous history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no previous history of antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering agents. Since changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m2. Among patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher and less than 60 mL/min/1.73m2, and who do not have other conditions that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum dose of 1000 mg daily. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, administration of this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases. The risk of volume depletion with dapagliflozin should be considered.

Precautions

This medication helps in controlling blood sugar; however, it should not be used in patients with impaired kidney function or acute illness. Rarely, it can cause a serious condition called lactic acidosis, which occurs when lactic acid accumulates excessively in the body and can be very dangerous, so seek immediate medical treatment if symptoms appear. Additionally, caution is warranted when used with insulin or other diabetes medications due to the risk of hypoglycemia. Patients with reduced kidney function, dehydration, severe infections, heart problems, liver dysfunction, or women who are pregnant or breastfeeding should not take this medication. In certain situations, such as surgery or radiological examinations, the intake of this medication should be temporarily suspended, and it should be restarted only after confirming normal kidney function. While taking this medication, genital infections, urinary infections, hypoglycemia, dehydration symptoms, dizziness, etc., may occur, so consult a doctor if unusual symptoms arise. Especially in elderly patients or those with decreased kidney function, regular kidney function tests should be conducted, and dosage should be adjusted accordingly. This medication may interact with other drugs; therefore, inform your healthcare provider of any other medications you are taking. It should not be used during pregnancy or breastfeeding, and its safety and efficacy have not been established in children. In the case of overdose, seek appropriate treatment at a medical institution immediately, and keep this medication out of reach of children.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • fluid volume depletion
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased blood creatinine
  • increased blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignant neoplasm
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature to ensure prolonged effectiveness.

Appearance and packaging

Appearance

Pink, biconvex, oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.